Advertisement
Document › Details
Valneva S.E.. (9/25/23). "Press Release: Valneva Announces New Ixiaro Supply Contract with the U.S. Government Worth a Minimum of $32 Million". Saint Herblain.
Region | United States (USA) | |
Organisation | Valneva S.E. (Nasdaq: VALN, Euronext Paris: VLA) | |
Group | Valneva (Group) | |
Organisation 2 | Department of Defense (DOD) (US) | |
Group | United States (govt) | |
Product | Ixiaro® | |
Person | Patel, Dipal (Valneva 202211– Chief Commercial Officer before GSK) | |
Person 2 | Drumm, Joshua (Valneva 202108 VP Global Investor Relations before AC Immune) | |
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®.
Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Deliveries will commence immediately.
Dipal Patel, Chief Commercial Officer of Valneva commented, “We are excited to continue our long-term relationship with the DoD. The U.S. military has trusted IXIARO® for over ten years to help protect military personnel, their families, civilian government service personnel, and government contractors from this potentially deadly disease.”
IXIARO® is the only JE vaccine approved by the U.S. Food and Drug Administration (FDA), having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. In the U.S., Valneva markets and distributes IXIARO® directly to the military and private travel market.
About Japanese Encephalitis
Japanese encephalitis is a deadly infectious disease found mainly in Asia. About 70,000 cases of JE are estimated to occur in Asia each year, although the actual number of cases is likely much higher due to underreporting in rural areas. JE is fatal in approximately 30 percent of those who show symptoms, and leaves half of survivors with permanent brain damage. The disease is endemic in Southeast Asia, India and China, a region with a population of more than three billion. In 2005, JE killed more than 1,200 children in only one month during an epidemic outbreak in Uttar Pradesh, India, and Nepal.
About Valneva SE
We are a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases. We take a highly specialized and targeted approach to vaccine development by focusing on vaccine solutions addressing unmet medical needs to ensure we can make a difference to peoples’ lives. We apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, and our established vaccine development capabilities, to develop vaccines against diseases which are not yet vaccine-preventable, or for which there are limited effective treatment options. Today, we are leveraging our expertise and capabilities to rapidly advance a broad range of vaccines into and through the clinic, including candidates against the chikungunya virus and Lyme disease.
Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com
Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com
Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to possible additional orders of IXIARO®. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, changing needs of the U.S. military, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Record changed: 2024-01-20 |
Advertisement
More documents for Valneva (Group)
- [1] Valneva S.E.. (8/1/24). "Press Release: Valneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate". Saint-Herblain & Schlieren....
- [2] Valneva S.E.. (7/22/24). "Press Release: CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World’s First Chikungunya Vaccine". Oslo & Saint-Herblain....
- [3] Valneva S.E.. (7/1/24). "Press Release: Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
- [4] Valneva S.E.. (11/10/23). "Press Release: Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, Ixchiq". Saint Herblain....
- [5] Valneva S.E.. (11/9/23). "Press Release: Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates". Saint Herblain....
- [6] Valneva S.E.. (11/7/23). "Press Release: Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference". Saint Herblain....
- [7] Valneva S.E.. (10/25/23). "Press Release: Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment". Saint Herblain....
- [8] NorthX Biologics. (7/3/23). "Press Release: NorthX Biologics, a Leading Nordic Development and Manufacturing Organisation Announces Acquisition of a Biologics Manufacturing Unit from Valneva". Matfors....
- [9] Valneva S.E.. (11/17/22). "Press Release: Valneva Appoints Dipal Patel as Chief Commercial Officer". Saint-Herblain....
- [10] Valneva S.E.. (10/4/22). "Press Release: Valneva Announces Closing of Upsized €102.9 Million Global Offering". Saint-Herblain....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top